Business
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
CAMBRIDGE, Mass., January 12, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
About this update from Sarepta Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":426,"url":"https://media.zenfs.com/en/business-wire.com/676b4c7352e137d9dce809df65ef15f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F1v1tPoNKc.kjggTgv5MjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg1MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/676b4c7352e137d9dce809df65ef15f0","width":480,"height":426}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025","length":115,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Preliminary ELEVIDYS net product revenue totaled $110.4 million for the fourth quarter and $898.7 million for full-year 2025","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Preliminary PMO net product revenues totaled $259.2 million for the fourth quarter and $965.6 million for full-year 2025","length":120,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Preliminary year-end 2025 cash, cash equivalents, restricted cash and investments balance of approximately $953.8 million","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":480,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., January 12, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.","length":446,"tagName":"p"},{"type":"text","content":"Financial Update* (preliminary and unaudited)","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total net product revenue of $369.6 million for the fourth quarter and $1.86 billion for full-year 2025. Sarepta’s net product revenue does not include collaboration, contract manufacturing or royalty revenue.","length":209,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Fourth quarter and full-year 2025 net product revenue for...